Last reviewed · How we verify
Serdolect — Competitive Intelligence Brief
phase 1
5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Serdolect (Serdolect) — University of Aarhus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Serdolect TARGET | Serdolect | University of Aarhus | phase 1 | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Serdolect — Competitive Intelligence Brief. https://druglandscape.com/ci/serdolect. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing